Market research

BLSM BlossomHill Therapeutics, Inc. Common Stock

NASDAQ USD Healthcare

Latest close

— —

Loading market data…

Test a moving-average rule with historical data.

Market facts

Market cap: 607M
P/E ratio: Not available
Analyst target: 32.2
Dividend yield: Not available
Beta: Not available

Loading price history…

Profile

Company facts

Exchange: NASDAQ
Currency: USD
Sector: Healthcare
Industry: Biotechnology
ISIN: Not available
Market cap: 607M
P/E ratio: Not available
Analyst target: 32.2
Dividend yield: Not available
Beta: Not available

About

About BlossomHill Therapeutics, Inc. Common Stock

BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment. Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS). BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.

Visit company website

Reported results

Fundamentals

Open this section to load reported financial history.

Annual returns

No comments yet

Start a focused discussion about BLSM.

BLSM BlossomHill Therapeutics, Inc. Common Stock

Price & volume

Company facts

About BlossomHill Therapeutics, Inc. Common Stock

Fundamentals

Earnings

Cash flow

Profitability

Valuation

Performance

Annual returns

Investor discussion

No comments yet